Use of Lecanemab for Patients With Cardiovascular Disease-Reference-Cited by-同舟云学术

Use of Lecanemab for Patients With Cardiovascular Disease

Published:2024-04-02 Issue:13 Volume:331 Page:1089
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Ko Darae¹²,Pascual-Leone Alvaro¹,Shah Sachin J.³

Affiliation:

1. Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts

2. Section of Cardiovascular Medicine, Boston Medical Center, Boston, Massachusetts

3. Center for Aging and Serious Illness and Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston

Abstract

This Viewpoint discusses lecanemab use and the risk of cerebral macrohemorrhage for patients with mild cognitive impairment or early dementia.

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jama/articlepdf/2816612/jama_ko_2024_vp_240023_1711564171.23179.pdf

Reference6 articles.

1. Lecanemab in early Alzheimer’s disease.;van Dyck;N Engl J Med,2023

2. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.;Sims;JAMA,2023

3. Lecanemab: appropriate use recommendations.;Cummings;J Prev Alzheimers Dis,2023

4. Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke.;Reish;N Engl J Med,2023

5. Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020.;Ko;JAMA Netw Open,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating Lecanemab Eligibility for Patients in Skilled Nursing Facilities With Alzheimer Disease or Mild Cognitive Impairment;Journal of the American Medical Directors Association;2024-08

2. Challenges for emergency departments: Anti‐amyloid therapy and amyloid‐related imaging abnormalities in persons with dementia;Journal of the American Geriatrics Society;2024-07-22

3. Aβ-Amyloid Lowering with Monoclonal Antibodies for Alzheimer's Disease: Appropriate Use Recommendations for Australasian Conditions;SSRN Electronic Journal;2024